Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
Authors:
- Maxime PalazzoMPMaxime Palazzo
- Catherine Lombard-BohasCLCatherine Lombard-Bohas
- Guillaume CadiotGCGuillaume Cadiot
- Tamara Matysiak-BudnikTMTamara Matysiak-Budnik
- Vinciane ReboursVRVinciane Rebours
- Marie-Pierre VulliermeMVMarie-Pierre Vullierme
- Anne CouvelardACAnne Couvelard
- Olivia HenticOHOlivia Hentic
- Philippe RuszniewskiPRPhilippe Ruszniewski
- 1 February 2013
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 25 (2) , 232-238
Abstract
An antiproliferative effect of somatostatin analogs was recently demonstrated. To identify factors associated with tumor control in a group of patients with well-differentiated malignant digestive neuroendocrine tumors treated with lanreotide. A retrospective study was conducted in 68 patients treated with lanreotide alone, with progression-free survival as the primary endpoint. The role of the following factors was searched for by univariate and multivariate analyses: age, sex, mode of discovery, site of the primary tumor, metastatic spread, Ki67 proliferation index, uptake on somatostatin receptor scintigraphy, pretreatment tumor growth, extent of liver involvement, resection of primary tumor, previous treatments, and tumor markers. Tumor progression was observed in 39/68 patients (57.4%). Median progression-free survival was 29 months. On multivariate analysis, a Ki67 proliferation index of up to 5% [hazard ratio (HR)=0.262, P=0.009], pretreatment stability (HR=0.241, P=0.008), and hepatic tumor load of up to 25% (HR=0.237, P=0.004) were significantly associated with disease stability under lanreotide therapy. In patients with well-differentiated malignant digestive neuroendocrine tumors, Ki67 proliferation index of up to 5%, stable disease before treatment, and low-to-moderate hepatic tumor involvement (≤ 25%) are associated with tumor control during lanreotide treatment. These data if confirmed in prospective trials will help in rationalizing the use of somatostatin analogs with antiproliferative intent.Keywords
This publication has 37 references indexed in Scilit:
- Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastasesCancer, 2008
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based StudyGastroenterology, 2007
- Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumorsCancer, 2005
- Surgical Treatment of Neuroendocrine Metastases to the LiverJournal of the American College of Surgeons, 2003
- Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver MetastasesWorld Journal of Surgery, 2002
- Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 yearsSurgery, 2001
- Method for Dissection of Mesenteric Metastases in Mid‐gut Carcinoid TumorsWorld Journal of Surgery, 2000
- An analysis of 8305 cases of carcinoid tumorsCancer, 2000
- Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumorsCancer, 1998